NexMed, Inc. (NASDAQ: NEXM), a developer of innovative treatments based on the NexACT® drug delivery technology, today announced that it has received a Notice of Allowance from the U.S. Patent & Trademark Office for its U.S. patent application entitled, "Prostaglandin Compositions & Methods of Treatment for Male Erectile Dysfunction." The 37 allowed claims extend to NexMed's proprietary topical treatment for erectile dysfunction -- Alprox-TD, and specifically, to the product's enabling technology, formulation and method of treatment.
